Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis

Marina Esteve¹, Eliseo Albert¹, Estela Giménez¹, Ester Colomer¹, Juan Carlos Hernández-Boluda^{2

3}, Rafael Hernani², José Luis Piñana², Carlos Solano^{2

3}, David Navarro^{4

5

6}

Affiliations

¹ Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
² Hematology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
³ Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
⁴ Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. david.navarro@uv.es.
⁵ Department of Microbiology School of Medicine, University of Valencia, Valencia, Spain. david.navarro@uv.es.
⁶ CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. david.navarro@uv.es.

Marina Esteve et al. Bone Marrow Transplant. 2024 Oct.

. 2024 Oct;59(10):1480-1482.

doi: 10.1038/s41409-024-02376-2. Epub 2024 Jul 20.

Marina Esteve¹, Eliseo Albert¹, Estela Giménez¹, Ester Colomer¹, Juan Carlos Hernández-Boluda^{2

3}, Rafael Hernani², José Luis Piñana², Carlos Solano^{2

3}, David Navarro^{4

5

6}

¹ Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
² Hematology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
³ Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
⁴ Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. david.navarro@uv.es.
⁵ Department of Microbiology School of Medicine, University of Valencia, Valencia, Spain. david.navarro@uv.es.
⁶ CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. david.navarro@uv.es.

No abstract available

References

1. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte R, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44. - DOI - PubMed
1. Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF. Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies. Open Forum Infect Dis. 2022;10:ofac687. - DOI - PubMed - PMC
1. Cassaniti I, Colombo AA, Bernasconi P, Malagola M, Russo D, Iori AP, et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transplant. 2021;21:1622–28. - DOI - PubMed
1. Solano C, Giménez E, Albert E, Piñana JL, Navarro D. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: a narrative review. J Med Virol. 2023;95:e29005. - DOI - PubMed
1. Giménez E, Guerreiro M, Torres I, Aguilar C, Albert E, Hernández-Boluda JC, et al. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir. Transpl Infect Dis. 2023;25:e1402. - DOI